DNA Group TR Ltd
TASE:DNA
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IL |
D
|
DNA Group TR Ltd
TASE:DNA
|
1B ILS |
Loading...
|
|
| JP |
|
Keyence Corp
TSE:6861
|
13.4T JPY |
Loading...
|
|
| CN |
|
Hangzhou Hikvision Digital Technology Co Ltd
SZSE:002415
|
299.5B CNY |
Loading...
|
|
| US |
|
Keysight Technologies Inc
NYSE:KEYS
|
40.5B USD |
Loading...
|
|
| US |
|
Teledyne Technologies Inc
NYSE:TDY
|
30.9B USD |
Loading...
|
|
| SE |
|
Hexagon AB
STO:HEXA B
|
252B SEK |
Loading...
|
|
| CN |
|
Zhonghang Electronic Measuring Instruments Co Ltd
SZSE:300114
|
193.2B CNY |
Loading...
|
|
| UK |
|
Halma PLC
LSE:HLMA
|
13.6B GBP |
Loading...
|
|
| US |
|
Trimble Inc
NASDAQ:TRMB
|
15.9B USD |
Loading...
|
|
| US |
|
Zebra Technologies Corp
NASDAQ:ZBRA
|
13.1B USD |
Loading...
|
|
| TW |
|
Chroma ATE Inc
TWSE:2360
|
409.6B TWD |
Loading...
|
Market Distribution
| Min | -85 210% |
| 30th Percentile | -8.6% |
| Median | 1.8% |
| 70th Percentile | 7.2% |
| Max | 23 652.1% |
Other Profitability Ratios
DNA Group TR Ltd
Glance View
DNA Group (T.R.)Ltd. engages in biotechnology. The firm's areas of activity include: the evaluation of bone density by measuring the velocity of the propagation of sound waves across the bone, using Bimmed, as well as the development of oral delivery of drugs, through its subsidiary, Entera Bio Ltd. Entera Bio Ltd focuses on the development of oral delivery of large molecules to address unmet medical needs. Entera Bio Ltd holds a patent, combining the following technologies: a synthetic molecule absorption enhancer, facilitating the absorption of large molecules and a proprietary formulation to prevent molecule degradation. Entera Bio Ltd’s proprietary oral delivery platform can be applied to a range of large molecules and biologicals. Entera Bio Ltd’s drugs are designated for the following medical conditions: Hypoparathyroidism and Osteoporosis.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for DNA Group TR Ltd is 168.6%, which is below its 3-year median of 2 209.1%.
Over the last 2 years, DNA Group TR Ltd’s Net Margin has increased from -4 202.9% to 168.6%. During this period, it reached a low of -4 202.9% on Dec 31, 2022 and a high of 7 220.9% on Jan 31, 2025.
